



**ROSE**<sup>®</sup>

RGA Group Research

# Getting a Grip on High-Cost Drugs



As payers continue to struggle with the surge in both the volume and cost of specialty drugs, RGA Group Research and ROSE<sup>®</sup> Program teams have identified a list of 180+ costly specialty drugs\* with their associated estimated costs.

## One of The Most Expensive Drivers of High-Cost Drugs

### Hemophilia & Bleeding Disorders

RGA has seen a significant increase in the number of claims exceeding \$2 million since 2005; one significant driver of these claims is hemophilia. While the drugs for hemophilia and other bleeding disorders are expensive, inappropriate management is much more costly. RGA's ROSE Program helps clients more effectively manage these difficult cases.



### Top 10 Most Expensive Drugs

**1. Glybera (not FDA-approved)**

Genetic Diseases

**2. Raviciti**

Genetic Diseases

**3. Lumizyme**

Lysosomal Storage Disorders

**4. Carbaglu**

Genetic Diseases

**5. Actimmune**

Genetic Disease

**6. Soliris**

Hemolytic Disorders

**7. Alprolix**

Hemophilia & Related

**8. Idelvion**

Hemophilia & Related

**9. Naglazyme**

Lysosomal Storage Disorders

### Of 183 high-cost\* specialty drugs studied



**69%**

exceeded \$100,000 average annual wholesale acquisition cost (WAC)

### Of 183 high-cost\* specialty drugs studied

**26%**

exceeded \$200,000 average annual wholesale acquisition cost (WAC)

